<DOC>
	<DOCNO>NCT02859259</DOCNO>
	<brief_summary>An oral dose healthy subject determine relative bioavailabilty BMS-626529 administer BMS-663068 ( Prodrug ) .</brief_summary>
	<brief_title>A Study Relative Bioavailability BMS-626529 Administered BMS-663068 ( Prodrug ) From 150mg Low-dose Extended-release Tablets Compared 600mg Reference Extended-release Tablets Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Target Population : Healthy subject determine clinically significant deviation normal medical surgical history , physical examination , vital sign measurement , 12lead ECG measurement , , clinical laboratory test result . Body mass index ( BMI ) 18.0 32.0 kg/mÂ² . 3 . Subject Reenrollment : This study permit reenrollment subject discontinue study pretreatment failure ( i.e. , subject randomized/ treat ) . If reenrolled , subject must reconsented . 4 . Age : Males Females , age 18 age majority 50 year , inclusive . 5 . Reproductive Status : Women childbearing potential ( WOCBP ) must negative serum/urine ( urine test allow screening Day 1 Period 1 ) pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ) within 24 hour prior start study drug . Women must breastfeed . Women childbearing potential must agree follow instruction method ( ) contraception ( Appendix 1 ) duration treatment study drug plus 5 halflives study drug ( 60 hour ) plus 30 day ( duration ovulatory cycle ) total 33 day posttreatment completion . Males sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment study drug plus 5 halflives study drug ( 60 hour ) . In addition , male subject must willing refrain sperm donation time . Azoospermic male exempt contraceptive requirement . Women childbearing potential continuously heterosexually active also exempt contraceptive requirement , still undergo pregnancy test described section . 1 . Medical History Concurrent Diseases : History chronic acute illness , gastrointestinal disease , gastrointestinal surgery within less 4 week dose , blood donation within 4 week dose , blood transfusion within 4 week dose , smoke within less 12 month prior dose , alcohol abuse , inability tolerate oral medication , inability venipunctured . Any sound medical , psychiatric and/or social reason determine investigator . 2 . Physical Laboratory Test Findings : Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign measurement , ECGs , clinical laboratory determination beyond consistent target population . 3 . Exposure investigational drug placebo within 4 week study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>